Exhibit 99.1
Patents Owned or Licensed by MedImmune, Inc.
Product/ |
| US Patent |
| Subject Matter |
| Expiration |
|
E. coli |
| 4,795,803 |
| Adhesin antigens |
| 1/3/2006 |
|
|
| 5,804,198 |
| Adhesin vaccines |
| 9/8/2015 |
|
|
| 6,291,649 |
| Anti-adhesin antibodies |
| 3/2/2005 |
|
|
| 6,500,434 |
| Chaperone and Adhesin Proteins: Vaccines, Diagnostic and Methods for Treating Infections |
| 4/23/2019 |
|
|
| 6,737,063 |
| FimH adhesin proteins and methods of use |
| 7/6/2021 |
|
Vitaxin |
| 5,753,230 |
| Use of antibodies anti-avb3 antibodies to inhibit angiogenesis in tumors and inflamed tissue |
| 5/19/2015 |
|
|
| 6,590,079 |
| Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| 1/30/2017 |
|
|
| 6,531,580 |
| Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| 6/24/2019 |
|
|
| 6,596,850 |
| Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| 1/30/2018 |
|
MEDI-507 |
| 5,730,979 |
| Anti-CD2 antibodies and their use in treating T-cell mediated immune responses |
| 3/24/2015 |
|
|
| 5,951,983 |
| Anti-CD2 antibodies and their use in treating T-cell mediated immune responses |
| 9/14/2016 |
|
|
| 5,817,311 |
| Use of anti-CD2 antibodies in treating T-cell mediated immune responses |
| 10/6/2015 |
|
|
| 6,849,258 |
| Anti-CD2 antibodies and their use in treating T-cell mediated immune responses |
| 7/18/2017 |
|
HPV |
| 6,261,765 |
| Disassembly/reassembly of Papillomavirus Virus Like Particles |
| 9/5/2017 |
|
|
| 6,165,471 |
| HPV capsomeres with reduced assembly capacity |
| 7/2/2018 |
|
|
| 6,153,201 |
| Oral Immunization with Papillomavirus Virus Like Particles |
| 3/9/2013 |
|
|
| 6,416,945 |
| Disassembly/reassembly of Papillomavirus Virus Like Particles |
| 9/5/2017 |
|
RSV |
| 5,824,307 |
| SynagisÒ & other anti-RSV antibodies and their use in treating or preventing RSV infection |
| 10/20/2015 |
|
|
| 5,582,827 |
| Immunoglobulin from plasma for treatment of RSV |
| 12/10/2013 |
|
|
| 4,800,078 |
| Treatment of respiratory disease caused by RSV using human gamma globulin |
| 1/24/2006 |
|
|
| 5,412,077 |
| Effective Antibody Titers Against Respiratory Viruses |
| 8/4/2020 |
|
|
| 6,565,849 |
| Methods of Enhancing Activity of Vaccines and Vaccine Compositions |
| 3/02/2021 |
|
|
| 6,818,216 |
| Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| 11/28/2020 |
|
Strep |
| 5,928,900 |
| Pad1 protein |
| 7/27/2016 |
|
|
| 5,981,229 |
| DNA encoding Exp1 and PlpA proteins |
| 11/9/2016 |
|
|
| 5,834,278 |
| DNA encoding pneumococcal MsrA |
| 5/1/2016 |
|
|
| 6,245,335 |
| Streptococcal choline binding proteins |
| 5/1/2017 |
|
|
| 5,736,367 |
| Vectors and Prokaryotes which Autocatalytically Delete Resistance |
| 4/7/2018 |
|
|
| 5,798,243 |
| Bacterial Peptide Methionine Sulfoxide Reductase an Adhesion Associated Protein, and Antibiotic Therapies |
| 5/1/2016 |
|
|
| 6,420,135 |
| Streptococcus pneumoniae polynucleotides and sequences |
| 10/03/17 |
|
|
| 6,503,511 |
| Derivatives of Choline Binding Proteins for Vaccines |
| 4/6/2019 |
|
|
| 6,582,706 |
| Streptococcus Pneumoniae Protein and Immunogenic Fragments for Vaccine |
| 12/21/2019 |
|
|
| 6,689,369 |
| Immunogenic pneumococcal protein and vaccine compositions thereof |
| 1/17/2022 | (a) |
|
| 6,784,164 |
| Choline binding proteins for anti-pneumococcal vaccines |
| 5/1/2017 |
|
|
| 6,833,356 |
| Pneumococcal protein homologs and fragments for vaccines |
| 3/10/2021 | (a) |
IL-9 |
| 5,157,112 |
| Antibodies which specifically bind mammalian T cell growth factor P40 |
| 10/20/2009 |
|
|
| 6,037,149 |
| DNA and RNA molecules that encode Met-IL-9 and their use for recombinant production |
| 8/23/2016 |
|
|
| 5,580,753 |
| DNA molecules encoding IL-9 and their use for recombinant production |
| 12/3/2013 |
|
|
| 5,734,037 |
| Nucleic acid molecules that hybridize to DNA encoding IL-9 |
| 5/23/2009 |
|
|
| 5,414,071 |
| Human IL-9 protein |
| 5/9/2012 |
|
|
| 5,164,317 |
| Method for enhancing proliferation of mast cells using IL-9 |
| 3/23/2010 |
|
|
| 5,132,109 |
| Method for enhancing IgG production using IL-9 and IL-4 |
| 10/5/2010 |
|
|
| 5,246,701 |
| Method to inhibit IgE production using anti-IL-9 antibodies or other IL-9 inhibitors |
| 10/5/2010 |
|
|
| 5,962,269 |
| Processes and hybridomas for producing anti-IL-9 receptor antibodies |
| 10/5/2016 |
|
|
| 6,261,559 |
| Treating asthmatic symptoms using anti-IL-9 antibodies |
| 8/23/2016 |
|
|
| 5,789,237 |
| Nucleic acid molecules that hybridize to DNAs encoding human and murine IL-9 receptors |
| 8/4/2015 |
|
|
| 5,750,377 |
| Methods for production of mammalian T cell growth factor P40 |
| 5/12/2015 |
|
|
| 5,116,951 |
| IL-9 receptor protein |
| 9/19/2010 |
|
|
| 5,587,302 |
| Nucleic acid molecules encoding mammalian T cell growth factor P40 |
| 12/24/2013 |
|
|
| 5,208,218 |
| Mammalian T cell growth factor P40 protein |
| 5/4/2010 |
|
|
| 5,180,678 |
| Methods of detecting IL-9 |
| 9/19/2010 |
|
|
| 6,602,850 |
| Method of treating asthma using soluble IL-9 receptor variants |
| 8/23/2016 |
|
|
| 6,645,492 |
| Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 8/23/2016 |
|
Ethyol |
| 5,292,497 |
| Improving toxicity profiles in chemotherapy |
| 3/29/2011 |
|
|
| 5,424,471 |
| Process for preparing crystalline forms |
| 7/13/2012 |
|
|
| 5,591,731 |
| Dosage forms of crystalline amifostine |
| 7/31/2012 |
|
|
| 5,824,664 |
| Agents and methods for inhibiting HIV viral and protein expression using compounds that belong to a family which contains amifostine |
| 10/20/2015 |
|
|
| 5,846,958 |
| Methods of stimulating hematopoietic progenitor cells using a compound that belong to a family which contains amifostine |
| 12/8/2015 |
|
|
| 5,906,984 |
| Methods of stimulating hematopoietic progenitor cells using specific compounds, which include amifostine |
| 2/17/2015 |
|
|
| 5,994,409 |
| Methods of treating toxicities associated with chemotherapy, a method of treating a nephrodisorder, and a method of treating xerostomia, all of which use a compound that belongs to a family which contains amifostine |
| 12/9/2017 |
|
|
| 6,051,563 |
| Subcutaneous administration, method of protecting against toxicities associated with ionizing radiation |
| 2/12/2017 |
|
|
| 6,127,351 |
| Methods of treating or protecting against toxicities associated with chemotherapy using a specific dosing regime, a method of stimulating bone marrow growth, and a method of treating myelodysplastic syndrome, all of which use a compound that belongs to a family which contains amifostine |
| 2/12/2017 |
|
|
| 6,218,377 |
| Methods of treating or protecting against toxicities associated with specific chemotherapy agents, and a method of protecting normal tissue in cancer patients, both of which use a compound that belongs to a family which contains amifostine |
| 2/12/2017 |
|
|
| 6,239,119 |
| Methods of treating damaged or infected mucosal tissue using a compounds that belongs to a family which contains amifostine |
| 4/26/2019 |
|
|
| 6,384,259 |
| Stable Amorphous Amifostine Composition and Methods for the Preparation and Use of the Same |
| 11/16/2018 |
|
|
| 6,407,278 |
| Stable Amorphous Amifostine Composition and Methods for the Preparation and Use of the Same |
| 11/16/2018 |
|
|
| 6,489,312 |
| Novel Pharmaceutical Formulations Comprising Aminoalkyl Phosphorothioates |
| 6/15/2019 |
|
|
| 6,586,476 |
| Methods for Treatment of Neuro and Nephro Disorders and Therapeutic Toxicities Using Aminothiol Compounds |
| 12/09/2017 |
|
|
| 6,573,253 |
| Methods of the Administration of Amifostine and Related Compounds |
| 2/12/2017 |
|
|
| 6,753,323 |
| Topical administration of Amifostine and Related Compounds |
| 9/27/2019 | (a) |
NeuTrexin |
| 5,716,960 |
| Cystalline glucuronate hydrate salt |
| 2/10/2015 |
|
|
| 4,853,221 |
| Method for treating non-small cell lung cancer, head and neck cancers and breast cancer |
| 8/1/2006 |
|
|
| 6,017,921 |
| Crystalline glucuronate salt |
| 1/13/2015 |
|
|
| 6,017,922 |
| Thermally stable crystalline non-salts |
| 5/18/2018 |
|
|
| 6,258,821 |
| Trimetrexate ascorbate and compositions comprising trimetrexate and ascorbic acid |
| 4/26/2019 |
|
|
| 6,258,952 |
| Methods of producing monohydrate |
| 5/18/2018 |
|
|
| 4,694,007 |
| Use of Trimetrexate as Antiparasitic Agent |
| 9/15/2006 |
|
|
| 4,677,219 |
| Substituted Benzonitriles |
| 7/17/2006 |
|
|
| 5,160,727 |
| Tumor Cell Sensitization Method |
| 3/21/2010 |
|
|
| 6,576,635 |
| Novel Compositions Comprising Trimetrexate |
| 10/26/2019 |
|
PALA |
| 5,491,135 |
| Methods of treating a viral infections (e.g., hepatitis B and C and secondary to HIV 1) |
| 2/13/2013 |
|
Platinum |
| 4,895,935 |
| Platinum Pharmaceuticals |
| 1/23/2007 |
|
|
| 4,895,936 |
| Platinum Pharmaceuticals |
| 1/23/2007 |
|
|
| 4,957,481 |
| Photodynamic therapeutic technique |
| 9/18/2007 |
|
CMV |
| 6,291,236 |
| Human CMV sequences and attenuated viruses | �� | 3/31/2015 |
|
|
| 5,925,751 |
| Human CMV sequences and attenuated viruses |
| 3/31/2015 |
|
|
| 5,721,354 |
| Human CMV sequences and attenuated viruses |
| 3/31/2015 |
|
|
| 6,040,170 |
| Human CMV sequences and attenuated viruses |
| 3/31/2015 |
|
|
| 6,635,477 |
| Human CMV sequences and attenuated viruses |
| 3/31/2015 |
|
EBV |
| 6,054,130 |
| Non-splicing variants of EBV gp350 protein and gene |
| 4/18/2014 |
|
|
| 5,824,508 |
| Non-splicing variants of EBV gp350 protein and gene |
| 4/18/2014 |
|
|
| 6,458,364 |
| Non-Splicing Variants of GP350/220 |
| 4/18/2014 |
|
|
| 6,692,749 |
| Non-Splicing Variants of GP350/220 |
| 4/18/2014 |
|
Influenza |
| 5,690,937 |
| Temperature sensitive mutants of influenza |
| 6/5/2015 |
|
|
| 6,090,391 |
| Recombinant tryptophan mutants of influenza PB2 gene |
| 2/23/2016 |
|
|
| 6,322,967 |
| Recombinant tryptophan mutants of influenza PB2 gene |
| 2/23/2016 |
|
|
| 6,528,064 |
| Recombinant tryptophan mutants of influenza |
| 2/23/2016 |
|
|
| 6,843,996 |
| Recombinant Temperature sensitive mutants of influenza |
| 6/5/15 |
|
HSV |
| 4,769,331 |
| Recombinant herpes simplex cloning methods and materials |
| 9/6/2005 |
|
|
| 4,859,587 |
| Recombinant herpes simplex vectors and vaccines |
| 8/22/2006 |
|
|
| 5,288,641 |
| Herpes simplex as a vector |
| 2/22/2011 |
|
|
| 5,328,688 |
| Recombinant herpes simplex with 34.5 gene knockout |
| 6/12/2011 |
|
|
| 5,599,691 |
| Herpes simplex as a vector |
| 2/4/2014 |
|
|
| 5,641,651 |
| Synthetic HSV promoters and uses |
| 6/24/2014 |
|
|
| 5,714,153 |
| Recombinant herpes simplex vaccines and vectors |
| 12/23/2012 |
|
|
| 5,922,328 |
| Gamma 34.5 mutants of herpes simplex viruses |
| 9/11/2016 |
|
|
| 6,071,692 |
| Herpes simplex as a gene expression vector and vaccine |
| 6/4/2004 |
|
|
| 6,120,773 |
| Gamma 34.5 gene modification of herpes simplex viruses |
| 9/19/2017 |
|
Negative Stranded RNA Viruses |
| 5,166,057 |
| Recombinant negative strand RNA viruses |
| 11/24/2009 |
|
|
| 5,578,473 |
| Recombinant negative strand RNA viruses |
| 11/24/2009 |
|
|
| 5,786,199 |
| Recombinant negative strand RNA viruses and vaccines |
| 7/28/2015 |
|
|
| 5,820,871 |
| Recombinant negative strand RNA viruses – bicistronic |
| 10/13/2015 |
|
|
| 5,840,520 |
| Recombinant negative strand RNA virus expression systems |
| 8/28/2009 |
|
|
| 5,854,037 |
| Recombinant negative strand RNA viruses |
| 12/29/2015 |
|
|
| 6,001,634 |
| Recombinant negative strand RNA viruses |
| 8/28/2009 |
|
|
| 6,022,726 |
| Attenuated negative strand RNA viruses and methods |
| 2/8/2017 |
|
|
| 6,316,243 |
| Recombinant attenuated double strand RNA viruses |
| 11/13/2018 |
|
|
| 6,764,685 |
| Recombinant parainfluenza virus expression systems and vaccines |
| 3/21/2020 |
|
|
| 6,811,784 |
| Recombinant parainfluenza virus expression systems and vaccines |
| 3/21/2021 |
|
VZV |
| 6,087,170 |
| VZV gene and mutant VZV viruses |
| 4/28/2014 |
|
|
| 6,713,296 |
| VZV gene, mutant VZV and immunogenic compositions |
| 4/28/2014 |
|
HMGB1 |
| 6,468,533 |
| Antagonists of HMG1 for treating inflammatory conditions |
| 2/11/2019 |
|
|
| 6,448,223 |
| Antagonists of HMG1 for treating inflammatory conditions |
| 2/11/2019 |
|
|
| 6,303,321 |
| Antagonists of HMG1 for treating inflammatory conditions |
| 2/11/2019 |
|
IFNα IFNR1 |
| 5,889,151 |
| Purified human alpha interferon receptor |
| 3/30/2016 |
|
|
| 5,886,153 |
| Antibodies directed against the alpha interferon receptor |
| 6/6/2016 |
|
|
| 5,731,169 |
| cDNA fragment coding the alpha interferon receptor gene and process for the preparation of a corresponding protein |
| 6/6/2015 |
|
|
| 5,861,258 |
| Use of the alpha interferon receptor and cells which express the receptor, for identification of alpha interferon agonists |
| 6/6/2016 |
|
|
| 5,919,453 |
| Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| 12/5/2016 |
|
|
| 6,787,634 |
| Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R) |
| 12/6/2014 |
|
|
| 6,475,983 |
| Water-soluble polypeptides having a high affinity for alpha and beta interferons |
| 11/5/2019 |
|
(a) Calculation of expiration date includes patent term adjustment